title: Influence of topical steroid treatment on maxillary sinusitis.
abstract: The clinical efficacy and adverse effects of budesonide administered as a nasal aerosol in addition to sinus washings and erythromycin therapy was assessed by comparison with placebo in a randomized, double-blind study of 40 patients with chronic or recurrent maxillary sinusitis. Most of the patients had been referred for operative treatment. Corticosteroid therapy, 400 micrograms daily, or placebo was continued for 3 months. Budesonide and antral irrigations reduced nasal symptoms more effectively than placebo, and there was a significantly greater reduction in facial pain and sensitivity in the budesonide group than in the placebo group. During the treatment period, mucosal thickening as evaluated by radiology decreased more clearly in the budesonide group than in the placebo group, but the difference did not reach statistical significance. The most frequently isolated bacteria were Staphylococcus aureus, Staphylococcus epidermidis and Haemophilus influenzae. Only 2 of 20 Haemophilus strains were beta-lactamase producers. The cellular picture was dominated by neutrophils in all secretions. There was no significant difference in clinical outcome between the two groups. Topical steroid therapy did not cause any adverse effects.
authors.affiliation: Dept. of O.R.L., Central Hospital, Jyväskylä, Finland.
authors.forename: Y
authors.initials: Y
authors.lastname: Qvarnberg
authors.forename: O
authors.initials: O
authors.lastname: Kantola
authors.forename: J
authors.initials: J
authors.lastname: Salo
authors.forename: M
authors.initials: M
authors.lastname: Toivanen
authors.forename: H
authors.initials: H
authors.lastname: Valtonen
authors.forename: E
authors.initials: E
authors.lastname: Vuori
mesh_terms: D000287:Administration, Topical; D000328:Adult; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D019819:Budesonide; D002908:Chronic Disease; D004311:Double-Blind Method; D004917:Erythromycin / Q000627:therapeutic use; D005260:Female; D005938:Glucocorticoids; D006192:Haemophilus Infections / Q000188:drug therapy; D006193:Haemophilus influenzae; D006801:Humans; D008297:Male; D015523:Maxillary Sinusitis / Q000188:drug therapy* / Q000382:microbiology; D008875:Middle Aged; D011282:Pregnenediones / Q000627:therapeutic use*; D013203:Staphylococcal Infections / Q000188:drug therapy
chemical_list: D000893:Anti-Inflammatory Agents; D005938:Glucocorticoids; D011282:Pregnenediones; D019819:Budesonide; D004917:Erythromycin